Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
NICE type 2 diabetes guideline
This summary provides recommendations on blood glucose targets, patient education, and includes a useful algorithm on blood glucose management
Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
NICE pancreatitis guideline
Summary of NICE guidance on pancreatitis covers managing complications, nutrition support, and referral for specialist treatment.
Educational resources
Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.
Ozempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA
Commissioned by Novo Nordisk Limited
Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼) SMC No. (2092)
Information intended for healthcare professionals only.
Related Guidelines in Practice articles
-
Diabetes: adapt management to account for cardiovascular disease risk
Professor Peter J Grant and Professor Francesco Cosentino highlight the key recommendations from the 2019 ESC/EASD guideline on diabetes, pre-diabetes, and CVD
-
Key learning points: diabetes in older people with frailty
Professor Alan Sinclair explains how care should be personalised and targets adapted for older people with diabetes, including an assessment of frailty
-
Type 2 diabetes: the role of the practice pharmacist
Muhammad Siddiqur Rahman highlights the integral role of practice-based pharmacists in managing type 2 diabetes
-
Co-morbidities in type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed
-
Type 2 diabetes: what are the benefits and risks of glucose-lowering agents?
Dr Kevin Fernando explains how SIGN 154 offers evidence-based guidance on glucose control therapies for people with type 2 diabetes